托珠单抗早期干预细胞因子释放综合征对嵌合抗原受体T细胞治疗的影响
莉莉 周, 世光 叶, 萍 李, 晓晨 唐, 爱斌 梁 · 2023
Read 托珠单抗早期干预细胞因子释放综合征对嵌合抗原受体T细胞治疗的影响 by 莉莉 周, 世光 叶, 萍 李, 晓晨 唐, 爱斌 梁 (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10834881.txt.
Description
Lili Zhou, Shiguang Ye, Ping Li, Xiaochen Tang, and Aibin Liang study whether giving a blocking drug early calms a dangerous immune storm after cell therapy, in a 2023 paper. The therapy, CAR-T, retools a patient's own immune cells to attack leukemia. A common side effect is cytokine release syndrome, a storm of immune signals that brings high fever and can turn deadly. The drug tocilizumab damps that storm.
The team reviewed 22 patients with acute lymphoblastic leukemia treated at their center between 2015 and 2021. One group got the drug early, after four hours of steady high fever; the other got it later, once the storm grew severe. No one in the early group died from the syndrome, and brain side effects did not rise. Most patients in the early group reached full remission. The authors conclude that early dosing cuts severe storms and refines care after this therapy.
Catalog record
| CREATOR | 莉莉 周, 世光 叶, 萍 李, 晓晨 唐, 爱斌 梁 |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |